Envelope for single drug dose

• US 20130068828A1
• Filed: 03/25/2011
• Published: 03/21/2013
• Est. Priority Date: 05/31/2010
• Status: Abandoned Application

• Current Assignee: Onedose Pharma, S.L.
• Original Assignee: Onedose Pharma, S.L.
• Inventors: Pardina Clar, Rosa
• Application Number:
  US13/700,498
• Publication Number:
  US 20130068828A1
• Time in Patent Office: Days
• US Class Current: 229/80.5
• CPC Class Codes: A61J 1/03 for pills or tablets containers for pills or tablets with special dispensing means therefor B65D83/04
• CPC Class Codes: A61J 1/10 Bag-type containers
• CPC Class Codes: B65D 2203/00 Decoration means, markings, information elements, contents indicators
• CPC Class Codes: B65D 75/30 Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding

Abstract

The invention relates to an envelope consisting of a flexible heat-sealable sheet, which includes a front surface and a rear surface laterally closed by at least one longitudinal weld, and on the other ends by a transversal weld, defining an inner cavity containing the drug in question, the front and rear surfaces of the envelope having on least one of the ends of the inner cavity protrusions consisting of a flap, separated from the inner cavity by a weld line or area. Said flap provides a surface for incorporating Braille markings in impact printing or ink printing, without affecting the air-tightness of the inner cavity. In one embodiment, said flap includes a precut line in an area adjacent to the inner cavity for tearing and removing the portion of the flap that incorporates the name of the drug, while preserving the integrity of the inner cavity.

Claims

1. Envelope for single drug dose of the type formed by a flexible heat-sealable sheet which includes a front surface (11) and a rear surface (12) laterally closed by at least one longitudinal weld (13) and on the opposed ends by means of two transversal welds (14) defining an inner cavity (15) containing the drug, characterised in that the front and rear surfaces (11, 12) of the envelope (1) have at least on one of the ends of the inner cavity (15) protrusions forming a flap (16) separated from the inner cavity (15) by a transversal weld line or area (14) providing a surface for the incorporation of Braille markings (3) or impact printings without affecting the air tightness of the inner cavity (15), the envelope (1) being formed out of a pre-printed sheet at least in those areas aimed at forming the front and rear surfaces (11, 12) of the inner cavity (15) and the flap (16) has in an area near to the inner cavity (15) a precut line (5) for tearing and separating the portion of the flap (16) incorporating the identification of the drug, preserving at the same time the integrity of the inner cavity (15).

3. The envelope of claim 1, characterised in that the flap (16) has at least a flat portion (17) forming the surface for the incorporation of Braille markings (3) or impact printings.

2. (canceled)

4. (canceled)